MorphoSys has obtained an exclusive option for international rights to develop and market Vivoryon Therapeutics's family of QPCTL inhibitors. The small molecule glutaminyl-peptide cyclotransferase-like inhibitors will be used to develop cancer therapies in combination with MorphoSys' own candidate tafasitamab, or MOR208, to treat relapsed/refractory diffuse large B-cell lymphomas.
MorphoSys gains option for Vivoryon's QPCTL inhibitors program
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.